Suppr超能文献

淋巴结阴性肝内胆管癌术后复发的基因预测指标

Genetic predictors of postoperative recurrence in node-negative intrahepatic cholangiocarcinoma.

作者信息

Zhang Bo, Wang Xiang-Yu, Yang Lu-Yu, Shen Xiao-Tian, Zhu Ying, Zhu Wen-Wei, Fan Jie, Lu Lu, Chen Jin-Hong

机构信息

Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China.

Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

Updates Surg. 2025 Apr 2. doi: 10.1007/s13304-025-02189-y.

Abstract

Recent studies have revealed the prognostic value of genetic alterations in intrahepatic cholangiocarcinoma (ICC). However, the influence of individual mutations on postoperative recurrence has not been comprehensively evaluated, especially for lymph node-negative cases. A total of 589 localized ICCs with clinically or pathologically negative lymph node (cN0M0 or pN0M0) from 3 independent cohorts were included. The impact of clinicopathological and mutational parameters on recurrence-free survival (RFS) and post-recurrence survival (PRS) was analyzed using the Cox proportional hazards model. The effect of prognostic mutations on RFS and PRS was estimated by Kaplan-Meier analysis. Extremes of survivorship analysis was used to reveal distinct genomic profiles between cases with very early recurrence (VER) and long-term no recurrence (LNR). Among the recurrent mutations, only TP53 and KRAS showed significant association with RFS in both of the two screening cohorts. In the validation cohort, TP53 and KRAS mutations were both independent predictors for shorter RFS. Compared with wild-type patients, TP53 and KRAS mutations were more frequently observed in VER group than in LNR group, and were more enriched in patients with intrahepatic and extra-hepatic recurrence (IER). Furthermore, TP53 mutation was significantly associated with worse survival and lower probability of repeated hepatectomy in patients suffered from recurrence. TP53 and KRAS mutations were important genetic predictors that correlated with earlier and more aggressive recurrence in node-negative ICC patients after surgery. Effective peri-operative therapies for these high-risk tumor biology are needed to improve the clinical outcome for related patients.

摘要

近期研究揭示了肝内胆管癌(ICC)基因改变的预后价值。然而,单个突变对术后复发的影响尚未得到全面评估,尤其是对于淋巴结阴性的病例。本研究纳入了来自3个独立队列的589例临床或病理淋巴结阴性(cN0M0或pN0M0)的局限性ICC患者。使用Cox比例风险模型分析临床病理和突变参数对无复发生存期(RFS)和复发后生存期(PRS)的影响。通过Kaplan-Meier分析评估预后性突变对RFS和PRS的影响。采用生存极端分析揭示极早期复发(VER)和长期无复发(LNR)病例之间不同的基因组特征。在复发突变中,仅TP53和KRAS在两个筛查队列中均与RFS显著相关。在验证队列中,TP53和KRAS突变均是RFS较短的独立预测因素。与野生型患者相比,VER组中TP53和KRAS突变的发生率高于LNR组,且在肝内和肝外复发(IER)患者中更为富集。此外,TP53突变与复发患者的较差生存和重复肝切除的较低概率显著相关。TP53和KRAS突变是重要的基因预测因素,与术后淋巴结阴性ICC患者更早、更具侵袭性的复发相关。需要针对这些高危肿瘤生物学特征采取有效的围手术期治疗措施,以改善相关患者的临床结局。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验